RUO Disclaimer: All QRM products are strictly for in vitro laboratory and research use only by qualified researchers in appropriate facilities. Nothing here implies, suggests, or recommends any diagnostic, therapeutic, or clinical application or use in humans or animals.
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
GLP1 (SM)
The compound that reshaped metabolic research forever. A GLP-1 receptor agonist studied across hundreds of peer-reviewed models for its role in glucose regulation, appetite signaling, and energy homeostasis.
Price range: $80.00 through $130.00
- +99% Purity
- Third-Party Tested
- COA Available
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
The compound that reshaped metabolic research forever. A GLP-1 receptor agonist studied across hundreds of peer-reviewed models for its role in glucose regulation, appetite signaling, and energy homeostasis.
About GLP1 (SM)
GLP1 (SM) belongs to a class of incretin-based research peptides derived from the endogenous glucagon-like peptide-1 hormone. The native peptide is secreted in response to nutrient intake and plays a central role in postprandial glucose regulation. GLP1 (SM) was developed as a long-acting analog with structural modifications that confer resistance to enzymatic degradation, extending its activity profile and making it a highly practical tool for sustained receptor engagement studies in research models.
The primary research profile of GLP1 (SM) centers on metabolic function. It has been extensively studied for its effects on energy intake reduction, caloric behavior signaling, and adipose tissue dynamics. Research consistently associates GLP-1 receptor activation with decreased food intake through central and peripheral receptor-mediated mechanisms, alongside favorable outcomes in fat mass reduction and body composition remodeling. These properties have positioned GLP1 (SM) as a benchmark compound in obesity and metabolic dysregulation research.
Beyond metabolism, GLP1 (SM) has attracted significant interest in cardiovascular and neurological research. Studies have investigated its association with reduced major adverse cardiovascular events in high-risk metabolic research models, as well as its potential role in neuroinflammation, cognitive pathway activity, and neurodegenerative disease models. Emerging research also points to activity in hepatic lipid pathways, renal signaling, and musculoskeletal preservation during caloric deficit states, broadening its relevance across multiple research disciplines.
Mechanism of Action
- GLP-1 Receptor Agonism: GLP1 (SM) binds and activates the GLP-1 receptor, a G protein-coupled receptor expressed across pancreatic, neural, cardiac, and gastrointestinal tissue research models. This broad receptor distribution underlies the compound’s wide-ranging research applications across multiple organ systems.
- Glucose-Dependent Insulin Secretion: Receptor activation stimulates insulin release from pancreatic beta cells in a glucose-dependent manner, meaning secretion is tied to ambient glucose levels. This mechanism is central to glycemic regulation research and is studied for its implications in reducing hypoglycemic risk in metabolic research models.
- Energy Intake and Feeding Behavior Signaling: GLP1 (SM) acts on hypothalamic receptor centers and vagal afferent pathways to modulate feeding behavior signaling and reduce food intake. Research models demonstrate significant reductions in caloric intake, making this pathway a primary target in metabolic dysregulation and energy homeostasis research.
- Gastric Motility Modulation: The compound slows gastric emptying, extending the postprandial period and contributing to sustained energy intake modulation. This mechanism is studied for its role in nutrient absorption dynamics and its contribution to overall caloric regulation in metabolic research models.
- Adipose and Hepatic Lipid Regulation: GLP-1 receptor activation has been investigated for direct and indirect effects on lipid metabolism, including reduced lipogenesis, enhanced fat oxidation, and decreased hepatic lipid accumulation. These effects make GLP1 (SM) a relevant model compound in fat mass reduction and NAFLD-related signaling research.
Research Highlights
GLP1 (SM) has become one of the most studied compounds in incretin research, with studies examining its effects on fat mass, body composition markers, and glycemic signaling across controlled research settings. Its extended half-life and sustained receptor engagement make it a practical model compound for longitudinal metabolic pathway investigations.
GLP-1 receptor activation has been extensively studied for its role in modulating food intake behavior through central and peripheral signaling pathways. GLP1 (SM) has been investigated as a tool for examining caloric intake reduction, meal termination signaling, and compensatory intake responses in research models, with its sustained activity profile supporting longer-duration feeding behavior studies.
Research has examined GLP1 (SM)'s effects on the relationship between fat mass and lean mass at the cellular level, alongside its influence on fat oxidation pathway activity. Studies have investigated how GLP-1 receptor activation shapes adipose tissue dynamics and metabolic remodeling in structured preclinical research environments.
GLP1 (SM) has been investigated across a range of cardiovascular signaling markers in high-risk metabolic research models, with studies examining endothelial function, inflammatory pathway activity, and cardiovascular event associations. Research has studied these endpoints both independently and in relation to the compound's metabolic signaling profile in controlled research settings.
Product Specifications
- Molecular Formula
- C₁₈₄H₂₉₁N₄₅O₅₉
- Molecular Weight
- 4113.58 g/mol
- CAS #
- 910463-68-2
- Sequence
- His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Universal Solvent
- Storage
- -20°C (lyophilized), 2-8°C (after preparation)
Reference
- Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
- Marso, S.P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://doi.org/10.1056/NEJMoa1607141
- Blundell, J., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, energy expenditure, gastric emptying, and body composition in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. https://doi.org/10.1111/dom.12932
